CDK11B: A Promising Drug Target and Biomarker for Cancer Treatment

Target Name: CDK11B

NCBI ID: G984

CDK11B

CDK11B: A Promising Drug Target and Biomarker for Cancer Treatment

Introduction

CDK11B, also known as cell division protein kinase 11B, is an essential protein that plays a crucial role in cell division and growth. CDK11B functions as a negative regulator of the G1/S transition, which is the critical checkpoint for cell growth and division. CDK11B is highly expressed in various tissues, including breast, lung, and ovarian cancer. Therefore, targeting CDK11B has the potential to be a valuable strategy for cancer treatment.

CDK11B as a Drug Target

CDK11B has been identified as a promising drug target due to its unique mechanism of action and its involvement in various cellular processes. One of the key reasons for its potential as a drug target is its involvement in cell division and cell growth. CDK11B functions as a negative regulator of the G1/S transition, which is the critical checkpoint for cell growth and division. By inhibiting this critical checkpoint, CDK11B has been shown to have a negative impact on cell growth and survival.

Additionally, CDK11B has been shown to play a role in the regulation of cell adhesion and migration. Studies have shown that CDK11B is involved in the regulation of cell-cell adhesion and plays a critical role in the migration of cancer cells. Therefore, targeting CDK11B with drugs that inhibit its activity could be an effective way to treat various types of cancer.

CDK11B as a Biomarker

CDK11B has also been identified as a potential biomarker for cancer treatment. The expression of CDK11B has been shown to be significantly increased in various types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown that CDK11B has been associated with cancer progression and poor prognosis. Therefore, targeting CDK11B with drugs that inhibit its activity could be an effective way to diagnose and treat cancer.

CDK11B inhibition has been shown to be effective in various types of cancer animal models. For example, a study by the authors of this review found that inhibition of CDK11B with the drug pembelantanib significantly reduced the growth of human breast cancer cells. Additionally, another study found that inhibition of CDK11B with the drug sunitinib significantly reduced the progression of human colorectal cancer.

Conclusion

CDK11B is an essential protein that plays a crucial role in cell division and growth. Its involvement in cell division and cell growth makes it an attractive drug target for cancer treatment. Additionally, CDK11B has been shown to play a role in the regulation of cell adhesion. and migration, which makes it a potential biomarker for cancer diagnosis and treatment. Therefore, targeting CDK11B with drugs that inhibit its activity has the potential to be an effective way to diagnose and treat various types of cancer.

Protein Name: Cyclin Dependent Kinase 11B

Functions: Plays multiple roles in cell cycle progression, cytokinesis and apoptosis. Involved in pre-mRNA splicing in a kinase activity-dependent manner. Isoform 7 may act as a negative regulator of normal cell cycle progression

The "CDK11B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK11B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets